BrightSpring Health Services, Inc. Common Stock (BTSG) Stock

Understand BrightSpring Health Services, Inc. Common Stock: how it makes money

BrightSpring delivers home-based pharmacy and skilled clinical care (infusion, home health, personal and rehab care) to Medicare, Medicaid, and commercially insured patients, earning reimbursement on each script or visit. Revenue is roughly 81% home-based pharmacy, with a smaller but faster-growing provider-services arm covering higher-acuity infusion and skilled nursing.

Profit is generated by per-script and per-visit fees fixed by Medicare and Medicaid schedules, so operating margin stays around 3% until the higher-acuity infusion and home-health mix dilutes the low-margin pharmacy base enough to lift the blended reimbursement rate.

Business quality (Mixed): Revenue is compounding at 23% YoY and the acute-infusion buildout is real, but a 3% operating margin and an IRA-driven $200M headwind to the core pharmacy segment mean the profitability story is still unproven at scale.

Valuation: At 32× earnings, BTSG trades 27% above the Healthcare Services average (25×).

Bull case

• Infusion is the growth engine: Specialty and infusion delivered 30% revenue growth and 31% script growth, showing the higher-acuity provider segment is scaling well ahead of the broader company. That mix shift is the key lever for lifting the blended operating margin above its current 3%.
• Geographic optionality in acute infusion: Acute infusion volume grew over 20% and management plans expansion into 12 to 15 additional states, capping the highest-growth service nowhere near its addressable footprint. Lower leverage and recent ratings upgrades give the balance sheet room for disciplined bolt-on acquisitions in that space.
• Cash generation is turning real: Operating cash flow is guided to approximately $600 million in 2026, meaning a 23% revenue growth rate is translating into tangible cash even while the company funds the multi-state infusion buildout.

Bear case

• IRA gutting the core pharmacy: IRA effects are expected to reduce home and community pharmacy revenue by approximately $200 million in 2026, and that segment already declined 8% year over year. Because pharmacy is roughly 81% of total revenue, the regulatory drag outweighs incremental provider growth for the near term.
• Premium multiple on thin margins: The stock trades at 32.2x earnings versus a 25x Healthcare Services industry average, a 27% premium. With operating margin at just 3%, that multiple already prices in a step-change in profitability that has not yet been demonstrated at scale.
• H2 comps flatter the trend: Management flagged that second-half comparisons remain difficult after an unusually strong prior-year period, so reported growth rates may decelerate even if underlying script and census volumes are steady on an absolute basis.

Related Companies (Healthcare Services; 8 comparable companies)

• Option Care Health, Inc. (OPCH)
• AdaptHealth Corp. (AHCO)
• Chemed Corporation (CHE)
• Aveanna Healthcare Holdings Inc. (AVAH)
• Community Health Systems, Inc. (CYH)
• DaVita Inc. (DVA)
• Addus HomeCare Corporation (ADUS)
• Universal Health Services, Inc. (UHS)